MTEM Projected Dividend Yield

Molecular Templates Inc ( NASDAQ : MTEM )

Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for cancer. Co. utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. In its wild-type form, SLT is thought to induce its own entry into a cell when proximal to the cell surface membrane, self-route to the cytosol, and enzymatically and irreversibly shut down protein synthesis via ribosome inactivation. Co. has developed ETBs to various targets, including PD-L1, CD38, and CTLA-4.

20 YEAR PERFORMANCE RESULTS